”You won’t hear from us until we have struck a deal”
Bavarian Nordic would have preferred not to say anything about the ongoing negotiations for its prostate cancer vaccine, but Wednesday’s news about an Ebola pact with J&J made that impossible.
BY STEFAN SINGH KAILAY
Bavarian Nordic wants to avoid a repeat performance of the adverse developments from the spring of 2011. Consequently, the company would have preferred to only talk about its Ebola vaccine this Wednesday as it announced news that it had struck a major licensing deal with Johnson & Johnson subsidiary Janssen concerning the vaccine.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Bavarian CFO: Order paves way for ultimate goal
For abonnenter
Bavarian looking for partnerships for cancer vaccine
For abonnenter
